A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Inclusion Criteria:
Exclusion Criteria:
rribeiro@eyepoint.bio833-393-7646
Gilbert, Arizona 85297, United States
info@eyepointpharma.com1.833.393.7646
St. Petersburg, Florida 33711, United States
Carmel, Indiana 46032, United States
Albuquerque, New Mexico 87109, United States
Florence, South Carolina 29501, United States
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com833-393-7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646
info@eyepointpharma.com1.833.393.7646